Michael Grövdal
Impact in
- Hematology top 5%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma Research and Treatments
-
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
-
- Epigenetics and DNA Methylation 5
- Histone Deacetylase Inhibitors Research 3
- Amyloidosis: Diagnosis, Treatment, Outcomes 2
- Protein Degradation and Inhibitors 1
- Hematology 10
- Acute Myeloid Leukemia Research 9
- Co-authors
- Mohsen Karimi (4 shared papers)Eva Hellström‐Lindberg (7 shared papers)Monika Jansson (4 shared papers)Sören Lehmann (3 shared papers)Hareth Nahi (3 shared papers)Stefan Deneberg (2 shared papers)Konstanze Döhner (2 shared papers)Christer Paul (2 shared papers)
In The Last Decade
Michael Grövdal
13 papers receiving 326 citations
Peers
Comparison fields: 5 of 34
- Hematology 237
- Genetics 47
- Molecular Biology 188
- Cancer Research 23
- Oncology 26
Countries citing papers authored by Michael Grövdal
This map shows the geographic impact of Michael Grövdal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Grövdal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Grövdal more than expected).
Fields of papers citing papers by Michael Grövdal
This network shows the impact of papers produced by Michael Grövdal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Grövdal. The network helps show where Michael Grövdal may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Grövdal, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2010 | 101 | |
| 2 | 2014 | 46 | |
| 3 | 2010 | 44 | |
| 4 | 2017 | 41 | |
| 5 | 2007 | 38 | |
| 6 | 2015 | 30 | |
| 7 | 2008 | 13 | |
| 8 | 2007 | 5 | |
| 9 | 2023 | 5 | |
| 10 | 2008 | 1 | |
| 11 | 2011 | 1 | |
| 12 | 2015 | 1 | |
| 13 | 2022 | 1 |
About Michael Grövdal
Michael Grövdal is a scholar working on Molecular Biology, Hematology, Genetics, Epidemiology and Surgery, having authored 13 papers that have together received 327 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (9 papers), Epigenetics and DNA Methylation (5 papers), Histone Deacetylase Inhibitors Research (3 papers), Hemoglobinopathies and Related Disorders (3 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (2 papers), Pneumocystis jirovecii pneumonia detection and treatment (1 paper) and Protein Degradation and Inhibitors (1 paper). The work is most often cited by research in Hematology (237 citations), Genetics (47 citations), Molecular Biology (188 citations), Cancer Research (23 citations) and Oncology (26 citations). Michael Grövdal has collaborated with scholars based in Sweden, Denmark and Norway. Frequent co-authors include Mohsen Karimi, Eva Hellström‐Lindberg, Monika Jansson, Sören Lehmann, Hareth Nahi, Stefan Deneberg, Konstanze Döhner, Christer Paul, Verena I. Gaidzik and Tomas J. Ekström. Their work appears in journals such as Blood, Clinical Cancer Research, Bone Marrow Transplantation, Blood Cancer Journal and Leukemia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.